![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CC2D1B |
Gene summary for CC2D1B |
![]() |
Gene information | Species | Human | Gene symbol | CC2D1B | Gene ID | 200014 |
Gene name | coiled-coil and C2 domain containing 1B | |
Gene Alias | Lgd1 | |
Cytomap | 1p32.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q5T0F9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200014 | CC2D1B | HCC1_Meng | Human | Liver | HCC | 1.98e-22 | 3.52e-02 | 0.0246 |
200014 | CC2D1B | HCC1 | Human | Liver | HCC | 1.25e-03 | 1.93e+00 | 0.5336 |
200014 | CC2D1B | HCC2 | Human | Liver | HCC | 1.45e-14 | 2.41e+00 | 0.5341 |
200014 | CC2D1B | S014 | Human | Liver | HCC | 2.31e-13 | 4.36e-01 | 0.2254 |
200014 | CC2D1B | S015 | Human | Liver | HCC | 6.18e-09 | 3.75e-01 | 0.2375 |
200014 | CC2D1B | S016 | Human | Liver | HCC | 2.47e-10 | 2.84e-01 | 0.2243 |
200014 | CC2D1B | S027 | Human | Liver | HCC | 4.36e-08 | 5.36e-01 | 0.2446 |
200014 | CC2D1B | S028 | Human | Liver | HCC | 1.50e-18 | 5.94e-01 | 0.2503 |
200014 | CC2D1B | S029 | Human | Liver | HCC | 2.43e-21 | 7.22e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CC2D1B | SNV | Missense_Mutation | c.2446G>C | p.Glu816Gln | p.E816Q | Q5T0F9 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
CC2D1B | SNV | Missense_Mutation | rs778402049 | c.857N>A | p.Arg286Gln | p.R286Q | Q5T0F9 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CC2D1B | SNV | Missense_Mutation | rs554593851 | c.1439N>T | p.Pro480Leu | p.P480L | Q5T0F9 | protein_coding | tolerated(0.23) | benign(0) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CC2D1B | SNV | Missense_Mutation | c.1187N>A | p.Arg396His | p.R396H | Q5T0F9 | protein_coding | tolerated(0.14) | benign(0.374) | TCGA-BH-A0B9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
CC2D1B | SNV | Missense_Mutation | rs768400113 | c.2300N>A | p.Arg767Gln | p.R767Q | Q5T0F9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A12Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CC2D1B | SNV | Missense_Mutation | c.253N>C | p.Asp85His | p.D85H | Q5T0F9 | protein_coding | tolerated(0.05) | possibly_damaging(0.541) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
CC2D1B | insertion | Nonsense_Mutation | novel | c.213_214insACGTAACACGTGTGTGGCCT | p.Ala72ThrfsTer2 | p.A72Tfs*2 | Q5T0F9 | protein_coding | TCGA-A8-A09T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
CC2D1B | SNV | Missense_Mutation | c.739N>G | p.Pro247Ala | p.P247A | Q5T0F9 | protein_coding | tolerated(0.16) | benign(0.006) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
CC2D1B | SNV | Missense_Mutation | c.2180N>A | p.Arg727Gln | p.R727Q | Q5T0F9 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
CC2D1B | SNV | Missense_Mutation | c.1945G>C | p.Glu649Gln | p.E649Q | Q5T0F9 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |